59581-9 |
Coxsackievirus A7 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Coxsackievirus A7 IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
Negative Titer results (i.e. 1:2, 1:4, etc.) |
|
|
|
|
|
MICRO |
|
59581-9 |
|
IF |
|
|
Both |
|
|
|
0 |
CV A7 IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; CAV; Coxsackie; Coxsackie virus; CV; CV A7; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59582-7 |
Coxsackievirus A24 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Coxsackievirus A24 IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
Negative Titer results (i.e. 1:2, 1:4, etc.) |
|
|
|
|
|
MICRO |
|
59582-7 |
|
IF |
|
|
Both |
|
|
|
0 |
CV A24 IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; CAV; Coxsackie; Coxsackie virus; CV; CV A24; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59583-5 |
Coxsackievirus A16 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Coxsackievirus A16 IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
Negative Titer results (i.e. 1:2, 1:4, etc.) |
|
|
|
|
|
MICRO |
|
59583-5 |
|
IF |
|
|
Both |
|
|
|
0 |
CV A16 IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; CAV; Coxsackie; Coxsackie virus; CV; CV A16; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59584-3 |
Coxsackievirus A7 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Coxsackievirus A7 IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
Negative Titer results (i.e. 1:2, 1:4, etc.) |
|
|
|
|
|
MICRO |
|
59584-3 |
|
IF |
|
|
Both |
|
|
|
0 |
CV A7 IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; CAV; Coxsackie; Coxsackie virus; CV; CV A7; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59585-0 |
GSTP1 gene+APC gene methylation |
Arb |
Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
GSTP1 gene+APC gene methylation [Presence] in Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
Positive Negative |
|
|
|
|
|
MOLPATH |
|
59585-0 |
|
Molgen |
|
|
Both |
|
|
|
0 |
GSTP1+APC gene methylation Tiss Ql |
|
|
|
N |
|
Adenomatosis polyposis coli; adenomatous polyposis coli; Adenomatous polyposis of the colon; Arbitrary; BTPS2; DNA methylation; DP2; DP2.5; DP3; Familial adenomatous polyposis; FAP; FPC; GS; GSTP1+APC gene methylation; Molecular genetics; Molecular pathology; MOLPATH; Ordinal; PCR; Point in time; PPP1R46; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified |
2.73 |
2.32 |
|
|
|
|
|
|
|
|
|
|
|
0 |
59586-8 |
HLA Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
HLA IgG Ab [Presence] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
Positive or Negative |
|
|
|
|
|
HLA |
|
59586-8 |
|
IF |
|
|
Both |
|
|
|
0 |
HLA IgG Ser Ql IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Cytotoxic-lymphocytic antibody; FA; Fluorescent antibody; Fluoresent; HLA ANTIGEN; Human Leukocyte Antigen; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Lymphocyte antibody; Lymphocytotoxic antibody; Ordinal; Panel Reactive AB; Panel Reactive antibody; Point in time; PR; PRA; QL; Qual; Qualitative; Random; Screen; Serum; SR; Time Resolved Fluorescence; TRF |
2.56 |
2.36 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
59587-6 |
Homovanillate |
MCnc |
Urine |
XXX |
Qn |
|
|
ACTIVE |
Homovanillate [Mass/volume] in Urine collected for unspecified duration |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
CHEM |
|
59587-6 |
|
|
|
|
Both |
|
|
|
0 |
HVA ?Tm Ur-mCnc |
|
|
|
N |
|
?Tm; 3-methoxy-4-hydroxy-phenylacetic acid; Chemistry; Homovanilic; Homovanillic acid; HVA; Level; Mass concentration; QNT; Quan; Quant; Quantitative; Tumor marker; UA; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
59588-4 |
1-Hydroxymidazolam |
MCnt |
Meconium |
Pt |
Qn |
|
|
ACTIVE |
1-Hydroxymidazolam [Mass/mass] in Meconium |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59588-4 |
|
|
|
|
Both |
|
|
|
0 |
1OH-midazolam Mec-mCnt |
|
|
|
N |
|
1-Hydroxy midazolam; 1OH-midazolam; Alpha hydroxymidazolam; Alpha-hydroxymidazolam; Chlonazepam metabolite; DRUG/TOXICOLOGY; Drugs; i; Mass content; Mec; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59589-2 |
1-Hydroxymidazolam |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
1-Hydroxymidazolam [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59589-2 |
|
|
|
|
Both |
|
|
|
0 |
1OH-midazolam Ur-mCnc |
|
|
|
N |
|
1-Hydroxy midazolam; 1OH-midazolam; Alpha hydroxymidazolam; Alpha-hydroxymidazolam; Chlonazepam metabolite; DRUG/TOXICOLOGY; Drugs; i; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
5959-2 |
Coagulation tissue factor induced.factor substitution^immediately after addition of normal plasma |
Time |
PPP |
Pt |
Qn |
Coag |
|
ACTIVE |
Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma |
|
MIN |
DefinitionDescription |
|
|
s |
|
|
|
|
|
|
COAG |
|
5959-2 |
|
Coag |
|
|
Observation |
|
|
|
0 |
PT imm NP PPP |
|
|
|
Y |
|
Clot; Clottable; Coag; Coagulation assay; Control; Fac; Fact; Hematology; Heme; imm NP; Immediatedly after 1:1 addition of; Mixing studies; Plas; Platelet poor plasma; Point in time; Pro time; Prothrombin time; Protime; PT; PT correction study; PT immediate mix; PT incubated mix; QNT; Quan; Quant; Quantitative; Random; Tilt tube |
2.73 |
1.0d |
|
|
|
|
|
|
|
s |
|
|
|
0 |
59590-0 |
1-Hydroxymidazolam |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
1-Hydroxymidazolam [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59590-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
1OH-midazolam Ur Cfm-mCnc |
|
|
|
N |
|
1-Hydroxy midazolam; 1OH-midazolam; Alpha hydroxymidazolam; Alpha-hydroxymidazolam; Cfm; Chlonazepam metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; i; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59591-8 |
7-Aminoclonazepam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
7-Aminoclonazepam [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59591-8 |
|
|
|
|
Both |
|
|
|
0 |
7Aminoclonazepam Bld-mCnc |
|
|
|
N |
|
7-amino clonazepam; 7Aminoclonazepam; Addiction; Blood; Clonazepam metabolite; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59592-6 |
7-Aminoclonazepam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
7-Aminoclonazepam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59592-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
7Aminoclonazepam Bld Cfm-mCnc |
|
|
|
N |
|
7-amino clonazepam; 7Aminoclonazepam; Addiction; Blood; Cfm; Clonazepam metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59593-4 |
7-Aminoclonazepam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
7-Aminoclonazepam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59593-4 |
|
|
|
|
Both |
|
|
|
0 |
7Aminoclonazepam Fld-mCnc |
|
|
|
N |
|
7-amino clonazepam; 7Aminoclonazepam; Addiction; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Clonazepam metabolite; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fl; Fld; FLU; Fluid; Illicit; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59594-2 |
7-Aminoclonazepam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
7-Aminoclonazepam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59594-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
7Aminoclonazepam Fld Cfm-mCnc |
|
|
|
N |
|
7-amino clonazepam; 7Aminoclonazepam; Addiction; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; Clonazepam metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fl; Fld; FLU; Fluid; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59595-9 |
7-Aminoclonazepam |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
7-Aminoclonazepam [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59595-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
7Aminoclonazepam SerPl Cfm-mCnc |
|
|
|
N |
|
7-amino clonazepam; 7Aminoclonazepam; Addiction; Cfm; Clonazepam metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59596-7 |
7-Aminoclonazepam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
7-Aminoclonazepam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59596-7 |
|
|
|
|
Both |
|
|
|
0 |
7Aminoclonazepam Tiss-mCnt |
|
|
|
N |
|
7-amino clonazepam; 7Aminoclonazepam; Addiction; Clonazepam metabolite; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Mass Content; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59597-5 |
7-Aminoclonazepam |
MCnt |
Tiss |
Pt |
Qn |
Confirm |
|
ACTIVE |
7-Aminoclonazepam [Mass/mass] in Tissue by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59597-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
7Aminoclonazepam Tiss Cfm-mCnt |
|
|
|
N |
|
7-amino clonazepam; 7Aminoclonazepam; Addiction; Cfm; Clonazepam metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Mass content; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59598-3 |
acetaZOLAMIDE |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Acetazolamide [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.5 ug/mL |
|
|
|
|
|
DRUG/TOX |
|
59598-3 |
|
|
|
|
Both |
|
|
|
0 |
acetaZOLAMIDE Bld-mCnc |
|
|
|
N |
|
Acetadiazol; Acetazolam; AK-Zol; Blood; Diamox; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59599-1 |
Alpha hydroxyalprazolam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Alpha hydroxyalprazolam [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59599-1 |
|
|
|
|
Both |
|
|
|
0 |
A-OH Alpraz Bld-mCnc |
|
|
|
N |
|
Alfa; Alpha hydroxy alprazolam; Alprozolam metabolite; A-OH Alpraz; Blood; DRUG/TOXICOLOGY; Drugs; Hydroxy alprazolam; Hydroxyalpraz; Level; Mass concentration; OH-Alpraz; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
596-7 |
Bacteria |
Prid |
Amnio fld |
Pt |
Nom |
Culture |
|
ACTIVE |
Bacteria identified in Amniotic fluid by Culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
596-7 |
|
Culture |
|
|
Both |
|
|
|
0 |
Bacteria Amn Cult |
|
|
|
|
|
AF; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; Bact; C&S; Cult; Cultures; Gyn; Gynecology; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; OB; ObGyn; Obstetrics; Point in time; Random |
2.78 |
1 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
5960-0 |
Coagulation tissue factor induced.factor substitution^20M post incubation.37 deg c after addition of normal plasma |
Time |
PPP^Control |
Pt |
Qn |
Tilt tube |
|
DEPRECATED |
Deprecated Prothrombin time (PT) factor substitution in Platelet poor plasma from control by Coagulation assay --20M post incubation with normal plasma |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
5960-0 |
|
Tilt tube |
|
|
|
|
|
|
0 |
Deprecated PT PPP Cont Qn |
|
|
|
|
|
@37c; 20M p Inc; After; Coag; Contrl; Control; degree; Fac; Fact; Hematology; Heme; Mixing studies; Normal; Plas; Platelet poor plasma; Point in time; Pro time; Prothrombin time; Protime; PST; PT; PT correction study; PT immediate mix; PT incubated mix; QNT; Quan; Quant; Quantitative; Random |
2.36 |
1.0d |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
59600-7 |
Alpha hydroxyalprazolam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Alpha hydroxyalprazolam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59600-7 |
|
Confirm |
|
|
Both |
|
|
|
0 |
A-OH Alpraz Bld Cfm-mCnc |
|
|
|
N |
|
Alfa; Alpha hydroxy alprazolam; Alprozolam metabolite; A-OH Alpraz; Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; Hydroxy alprazolam; Hydroxyalpraz; LC/MS/MS; Level; Mass concentration; OH-Alpraz; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59601-5 |
Alpha hydroxyalprazolam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Alpha hydroxyalprazolam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59601-5 |
|
|
|
|
Both |
|
|
|
0 |
A-OH Alpraz Fld-mCnc |
|
|
|
N |
|
Alfa; Alpha hydroxy alprazolam; Alprozolam metabolite; A-OH Alpraz; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Hydroxy alprazolam; Hydroxyalpraz; Level; Mass concentration; OH-Alpraz; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59602-3 |
Alpha hydroxyalprazolam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Alpha hydroxyalprazolam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59602-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
A-OH Alpraz Fld Cfm-mCnc |
|
|
|
N |
|
Alfa; Alpha hydroxy alprazolam; Alprozolam metabolite; A-OH Alpraz; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; GCMS; Hydroxy alprazolam; Hydroxyalpraz; LC/MS/MS; Level; Mass concentration; OH-Alpraz; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |